-
公开(公告)号:US20220003784A1
公开(公告)日:2022-01-06
申请号:US17280202
申请日:2019-09-26
申请人: ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE D'AIX-MARSEILLE , QUEEN MARY UNIVERSITY OF LONDON , SORBONNE UNIVERSITÉ
发明人: AURÉLIE LEROYER , MARCEL BLOT-CHABAUD , CHRISTOS CHADJICHRISTOS , NATHALIE BARDIN , FRANÇOISE DIGNAT-GEORGE , ALEXANDRINE BERTAUD , BENJAMIN GUILLET , CHRISTOPH THIEMERMANN , GUILLAUME HACHE
摘要: The present invention relates to the field of medicine and in particular to the diagnostic and treatment of fibrosis. More particularly, the invention relates to CD146 and uses thereof as a biomarker in the diagnosis of fibrosis and as a therapeutic target in the treatment of fibrosis. The invention also relates to compositions and methods of detecting predisposition to, of diagnosing, prognosing and/or monitoring fibrosis in a subject. It further relates to CD146 inhibitors, and to compositions comprising a CD146 inhibitor, for use in prevention or treatment of fibrosis in a subject, as well as to compositions, kits and uses thereof in a diagnostic or therapeutic context.
-
公开(公告)号:US20200262929A1
公开(公告)日:2020-08-20
申请号:US16652079
申请日:2018-10-05
申请人: UNIVERSITE D'AIX-MARSEILLE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE
发明人: MARCEL BLOT-CHABAUD , BENJAMIN GUILLET , MARIE NOLLET , JIMMY STALIN , NATHALIE BARDIN , FRANÇOISE DIGNAT-GEORGE
摘要: The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.
-
3.
公开(公告)号:US20200232989A1
公开(公告)日:2020-07-23
申请号:US16632402
申请日:2018-07-20
申请人: UNIVERSITE D'AIX-MARSEILLE , UNIVERSITE COTE D'AZUR , ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
IPC分类号: G01N33/574
摘要: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a cancer, in particular renal cell carcinoma (RCC) to sunitinib, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.
-
4.
公开(公告)号:US20180164323A1
公开(公告)日:2018-06-14
申请号:US15568097
申请日:2016-04-21
申请人: UNIVERSITE D'AIX-MARSEILLE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE DE MONTPELLIER , CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES , ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
发明人: NATHALIE BARDIN , MARCEL BLOT-CHABAUD , SYLVIE BOUVIER , ODILE LACROIX , FRANCOISE DIGNAT-GEORGE , JEAN-CHRISTOPHE RAYMOND GRIS
IPC分类号: G01N33/68 , A61B17/435
摘要: The present invention relates to the field of human fertility treatment. The present invention more specifically relates to the identification of soluble CD146 (sCD146) as a biomarker which, when measured in an embryo culture medium, can be used to determine whether the embryo can be selected for implantation in the uterus of a mammal or not. The present invention thus provides a new tool and related kits to (pre)select embryo eligible for implantation. The invention also relates to methods for promoting pregnancy in a human who undergoes embryo transfer.
-
公开(公告)号:US20170218082A1
公开(公告)日:2017-08-03
申请号:US15462952
申请日:2017-03-20
申请人: UNIVERSITE D'AIX-MARSEILLE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
发明人: MARCEL BLOT-CHABAUD , KARIM HARHOURI , NATHALIE BARDIN , BENJAMIN GUILLET , FRANCOISE DIGNAT-GEORGE
IPC分类号: C07K16/30
摘要: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.
-
-
-
-